Lumos Pharma (NASDAQ:LUMO) Trading Up 2.4% – Time to Buy?

Lumos Pharma, Inc. (NASDAQ:LUMO)’s stock price shot up 2.4% during mid-day trading on Friday . The stock traded as high as $4.04 and last traded at $3.87. 15,631 shares were traded during trading, a decline of 63% from the average session volume of 42,306 shares. The stock had previously closed at $3.78.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on LUMO. EF Hutton Acquisition Co. I raised shares of Lumos Pharma to a “strong-buy” rating in a research note on Tuesday, September 24th. HC Wainwright reiterated a “buy” rating and issued a $28.00 price target on shares of Lumos Pharma in a research report on Friday, September 27th. Finally, Oppenheimer cut their price objective on Lumos Pharma from $16.00 to $13.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd.

Lumos Pharma Trading Up 2.4 %

The company’s 50 day simple moving average is $3.63 and its 200-day simple moving average is $2.78. The company has a market capitalization of $31.41 million, a price-to-earnings ratio of -0.84 and a beta of 0.78.

Lumos Pharma (NASDAQ:LUMO) last announced its earnings results on Thursday, August 1st. The company reported ($0.93) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.26) by $0.33. Lumos Pharma had a negative net margin of 2,405.72% and a negative return on equity of 157.99%. The firm had revenue of $0.49 million for the quarter. During the same quarter last year, the business posted ($1.09) EPS. Sell-side analysts anticipate that Lumos Pharma, Inc. will post -2.96 EPS for the current year.

About Lumos Pharma

Lumos Pharma, Inc, a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders.